pigenetics is defined as heritable traits that are not linked to changes in the DNA sequence; however, in broader terms, epigenetics is used to describe the mechanisms by which chromatinassociated proteins and post-translational modifications (PTMs) of histones regulate transcription. Although all cells within an organism contain the same DNA, epigenetic regulators and transcription factors organize the genome into accessible and closed regions, which ensure the correct transcriptional program in a given cell type. Thus, epigenetic regulation is important for maintaining cell identity and is implicated in fundamental processes such as proliferation, development, differentiation and genome integrity. Epigenetic gene regulation can be mediated through DNA methylation, nucleosome remodelling, exchange of histone variants and PTMs of the histones (Box 1). Histones can be modified at specific amino acids with a diverse set of chemical modifications, such as phosphorylation, acetylation, methylation, ubiquitination or SUMOylation 1, 2 . Research in the past decade has led to a better understanding of the significance of these PTMs. In particular, this progress has been achieved through the identification of chromatin-associated proteins that catalyse, recognize and remove the specific modification (Box 1), the generation of high affinity antibodies specific for the PTM, genome-wide location analysis and genetic studies.
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Deregulation of epigenetic control is a common feature of a number of diseases, including brain disorders and cancer 3 . The involvement of DNA methylation in cancer has been appreciated for a number of years, and the approval of the first drugs targeting DNA methylation is a hallmark for epigenetic-based therapies. The two approved drugs, azacitidine (5-azacytidine) and decitabine (5-aza-2ʹ-deoxycytidine), are nucleoside analogues and irreversible inhibitors of the DNA methyltransferase enzymes DNMT1 and DNMT3. They are currently used as first-line treatments for patients with myelodysplastic syndrome 4, 5 . Shortly after the approval of the two DNA methylation inhibitors, the two histone deacetylase (HDAC) inhibitors suberoylanilide hydroxamic acid (SAHA) and romidepsin (depsipeptide or FK228) were approved for the treatment of refractory cutaneous T-cell lymphoma 6, 7 . Although the introduction of these drugs in the clinic has been a tremendous success for the field, a number of scientific challenges remain. Despite many years of research, we do not understand exactly how and why these drugs work. For HDAC inhibitors, acetylation is in general increased following drug treatment; however, data demonstrating a correlation between HDAC activity and therapeutic index is still lacking. Similarly, so far there is no established gene expression signature or profile that can predict whether a patient will benefit from the use of HDAC inhibitors. The picture is very similar for DNMT inhibitors. Although these molecularly targeted drugs have the potential to revert the epigenetic modification and have been shown to lead to global hypomethylation, we do not know their precise mechanism of action. For both classes of drug, the lack of reliable molecular biomarkers for predicting either clinical activity or resistance is a serious drawback, limiting clinicians' ability to achieve the vision of 'personalized medicine' . Despite a large number of clinical trials, the use of the four drugs is so far limited to specific haematological cancers.
Recently, the use of next-generation sequencing technologies on DNA isolated from primary tumours has revealed a high frequency of somatic mutations in genes coding for chromatin-associated proteins that are known to regulate DNA methylation patterns, histone PTMs and chromatin remodelling (see ref. 8 for a review). Strikingly, the discovery that patients with leukaemia often have mutations in genes such as TET2, IDH1, IDH2 and DNMT3A, which are all involved in regulating DNA methylation patterns, might provide insight into why patients with leukaemia show a significant response to DNA methylation inhibitors, and could hold promise for future patient stratification strategies. In fact, the lack of genetic data to support the role of chromatin-associated proteins in cancer has been a major obstacle for the development of patient-specific targeted therapies. This has drastically changed with the recent findings that chromatin-associated proteins often show aberrant expression in cancer as a result of translocations or genetic amplifications, and by the discovery that they carry specific somatic mutations.
In this Review, we will focus on the recent advances made by the scientific and pharmaceutical communities to develop highly potent and specific inhibitors to chromatin-associated proteins (Table 1) . These represent several new classes of therapeutic targets and, as we will exemplify, recent results have shown the feasibility of developing specific inhibitors to histone methyltransferases (HMTs), histone demethylases and domains required for the binding of protein complexes to specific histone modifications. This is a very exciting time for the field, in which the combination of knowledge regarding the role of chromatin-associated proteins in disease and the development of potential new classes of epigenetic drugs will hopefully lead to molecularly targeted and lower toxicity therapies with a clear genetic marker or markers for patient stratification.
Targeting histone methyltransferases
An association between histone hypermethylation, transcriptional regulation and the cancer phenotype has spurred efforts to develop specific, small molecule inhibitors of the methyltransferase enzymes involved in histone lysine and arginine methylation. The family of HMTs (or more accurately, protein methyltransferases; that is, protein arginine methyltransferases (PRMT) and protein lysine methyltransferases (KMTs)) encompasses over 60 different proteins that sequentially transfer a methyl group from the cofactor S-adenosylmethionine (SAM) to the terminal amine of specific substrate lysine and/or arginine residues. With the notable exception of the HMT DOT1L (see later), the catalytic transfer of a methyl group from SAM occurs within a conserved SET domain, which accommodates the cofactor and peptide substrates in a conformation conducive for an SN2 transfer reaction generating S-adenosylhomocysteine (SAH) and the methylated histone side chain as products (Fig. 1) . Detailed structural determinations of multiple SET-domain-containing HMTs have been carried out to support this mechanistic rationale for the methyl transfer event with a detailed analysis of binding modes of cofactor and/or peptide substrates to allow the rational design of selective inhibitors. An understanding of exactly how the degree of histone lysine methylation modulates transcription remains to be attained, but the need for the coordinated recruitment of methylation-sensitive proteins to transcriptional complexes offers one plausible hypothesis. Interestingly, the HMTs have also been reported [9] [10] [11] to act on various non-histone protein substrates to regulate their functions. However, the relative contributions of the histone compared with non-histone action of HMTs are not well understood and continue to be an area of active investigation.
In the context of cancer, the discovery of genetic alterations in HMTs in several different tumour types [12] [13] [14] has undoubtedly attracted much attention and provided additional support for the importance of epigenetic deregulation in a disease that is widely considered to be genetically driven. In some cases (such as the methyltransferase EZH2, discussed later), heterozygous point mutations in the catalytic SET domain lead to a gain of function of the wild-type enzyme 15, 16 , favouring trimethylation and the silencing of tumour suppressor genes and/or differentiation-specific genes. Similarly, in other cancers (such as, increased expression of NSD2 in multiple myeloma) chromosomal translocations result in increased expression of the methyltransferases, again leading to aberrant transcription and proliferation 17 . Conversely, lysine methylation induced by the HMT DOT1L results in sustained expression of several genes required for leukaemogenesis. Therefore, small molecule inhibitors, of for instance EZH2 or DOT1L, should be able to reduce or eliminate the site-specific lysine methylation introduced by the HMTs and reverse the oncogenic state (see later).
DOT1L
Chromosomal translocations are relatively common in various haematopoietic malignancies and can be associated with aggressive or poorly responsive disease. In leukaemia that involves rearrangement of the MLL (also known as KMT2A) gene, translocation leads to fusions with more than 50 different protein partners including ENL, ELL, AF4 and AF9 (ref. 18) (Fig. 2a) . The resulting fusion complexes recruit DOT1L, which specifically methylates the core histone H3 residue lysine 79 (H3K79) and contributes to transcriptional activation of HOXA10, MEIS1 and other genes required for leukaemia initiation 19 . DOT1L lacks the SET domain that is commonly present in other lysine methyltransferases but nonetheless can readily catalyse the transfer of one, two or three methyl groups to the ε-NH2 group of H3K79. In a crucial paper from the Armstrong laboratory 20 , deletion of DOT1L in MLL-rearranged cell lines and subsequently in in vivo mouse studies directly demonstrated the role of the enzyme not only in introducing the H3K79 methyl mark, leading to a concomitant increase in gene expression, but also in the development of the leukaemia.
Given the significant role of DOT1L in MLL-rearranged leukaemia, inhibitors of its H3K79 methyltransferase activity have been aggressively pursued as potential therapeutics. EPZ004777, a SAM-competitive pyrrolopyrimidine derivative (Fig. 2b) was designed 21 to mimic both SAM and the reaction product SAH while also taking advantage of potential hydrophobic interactions available in the binding vicinity. The compound is an extremely potent and remarkably selective SAM-competitive inhibitor of the enzyme. In MLL-rearranged cell lines, EPZ004777 reduces global H3K79me2 levels, blocks the expression of MLL-fusion target genes and has antiproliferative activity 21 . Consistent with a targeted mechanism of action, only cell lines with an MLL gene fusion were DNA is wrapped around histones (H2A, H2B, H3 and H4) to form nucleosomes. Nucleosomes are further compacted to form condensed chromatin. The compaction of DNA is in part regulated through post-translational modifications (PTMs) of the histone tails, which protrude from nucleosomes. Epigenetic regulators can in popular terms be divided into erasers, writers or readers of PTMs. The erasers, such as histone deacetylases and histone demethylases, remove the PTMs and prepare the histones for other modifications. The writers comprise enzymes such as histone acetylases, kinases, DNA and histone methyltransferases and ubiquitin ligases. The writers catalyse the PTMs on the DNA or the proteins, and may impose epigenetic heritability such as DNA methylation through copying and maintaining the modification. Other modifications, such as histone acetylation, respond rapidly to environmental stimuli and are therefore more dynamic. Readers of the post-translational modification include proteins with specific domains, such as bromo-, chromo-, tudor-, MBT-, PWWP-, WD40-and PHD-domains, which bind to the specific modification. The readers, which are often found in large protein complexes, interpret the modification and impose changes in chromatin structure.
BOX 1
The role of DNA and histone PTMs 
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sensitive to the DOT1L inhibitor whereas non-rearranged lines remained unaffected. Regardless of the measured parameter, the kinetics of cellular response to DOT1L inhibition (and other epigenetic drugs reported so far) is strikingly distinct to the more rapid response usually seen within a few hours with signal transduction modulators (kinase inhibitors) or nonspecific chemotherapeutic drugs. Thus, the maximal effect on depletion of the methyl mark is typically seen only after 4-5 days of exposure to the drug. Similarly, significant transcriptional changes occur after 6-8 days and more than 10 days are required to observe an antiproliferative phenotype. Defining and understanding these distinctive characteristics have important implications for the development of these agents because established measures of biomarker-based pharmacodynamic and/or early clinical response may be inappropriate. In addition, prolonged exposure to the drug may be required for efficacy, further highlighting the need for a selective compound with presumably lower propensity for undesirable off-target effects. Encouragingly, in preclinical experiments, EPZ004777 seemed to be well tolerated when given to mice at efficacious doses 21 . Unfortunately, notwithstanding these attractive attributes, poor pharmacokinetics -including a short plasma half-life -requires EPZ004777 to be administered as a 7 day continuous infusion using surgically implanted mini-osmotic pumps. In a preclinical setting, such studies are readily conducted but can pose significant challenges in clinical studies involving patients with cancer. In an attempt to address these shortcomings, further modifications of the pyrrolopyrimidine core of EPZ004777 have been investigated 22 as an approach to designing second-generation DOT1L-targeting drugs. For example, the Structural Genomics Consortium (SGC) has described bromo-deaza-SAH (Fig. 2b) as a convenient DOT1L inhibitor, allowing for the generation of X-ray co-crystal structures and hence the rational design of new analogues with improved properties 23 . The recent initiation, by the biotech company Epizyme, of clinical trials to determine the safety and efficacy of the DOT1L inhibitor EPZ-5676 (ref. 24) in patients with MLL leukaemia is highly significant and represents the first human study of a 'targeted' HMT inhibitor.
EZH2
The enzyme EZH2 is the catalytic component of the Polycomb protein complex PRC2 and acts as an HMT at H3K27. Importantly, in cell-free systems the EZH2 subunit is only catalytically competent when in a complex with at least two non-enzymatic partners (EED and SUZ12) and moreover in a physiologically relevant, intracellular context, the complex is known to contain two additional proteins (AEBP2 in complex with either RBBP4 or RBBP7) 25 ( Fig. 2c ). PRC2 maintains the transcriptional repression of a large number of genes with key regulatory roles in development and differentiation, and PRC2 proteins are required for normal embryonic development 25 . Pioneering studies from the Chinnaiyan lab have shown an association between increased levels of both EZH2 and H3K27me3 and poor outcomes in metastatic prostate cancer 26 . In addition, inactivating mutations in UTX, an H3K27 demethylase 27, 28 , are also similarly correlated, suggesting a key role for H3K27 hypermethylation in prostate cancer. Other studies have revealed a similar relationship between elevated levels of EZH2 with silencing of EZH2 target genes and poor prognosis in solid tumours, including breast, kidney and lung [29] [30] [31] [32] . More recently, somatic activating mutations in the SET domain of EZH2 have been identified in follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL), leading to increased H3K27me3 (refs 33-35) . Taken together, these findings suggest that misregulation of H3K27me3 levels, through EZH2 overexpression or point mutations, silences target genes that are important to tumour growth and survival and make a compelling case for targeting the enzyme therapeutically. Paradoxically, however, inactivating mutations in EZH2 have also been reported in myelodysplastic syndrome 36 , raising the potential of a tumour suppressor function for the protein. The role of EZH2 and H3K27 methylation in promoting or inhibiting tumorigenesis and/or maintenance seems therefore to be context dependent and, based on the potential for deleterious effects, suggests caution should be taken in developing chronically administered therapeutic inhibitors. Despite these potential drawbacks, multiple pharmaceutical and biotech company research groups have developed highly potent, selective, small molecule inhibitors of EZH2 (refs 37-39) , and other investigators have pursued equally interesting natural-product-based inhibitors 40 .
The medicinal chemistry design of HMT inhibitors has sought to take advantage of the intrinsic affinity of EZH2 for both SAH (K i = 7.5 uM) and lysine-containing substrate mimetics. Hybrid molecules (such as that shown in Fig. 2d ) that contain discrete elements of both recognition motifs are modest inhibitors and presumably act as classical bisubstrate inhibitors 41 . However, the relatively low permeability of these highly charged compounds might limit their use in cell-based assays and in vivo. By contrast, despite being devoid of direct EZH2 inhibitory activity, the structurally related and widely used 3-deazaneplanocin (DZNep; Fig. 2d ) has been shown to reactivate indirectly PRC2-silenced genes in cancer cell lines by depleting PRC2 subunits 42 . Unfortunately, this activity does not allow for differentiation of selective catalytic inhibition of EZH2 from more global effects of depleting PRC2, including loss of scaffolding functions, microRNA binding sites and so on, and complicates the interpretation of cellular phenotypes resulting from true inhibition of H3K27 methylation 43 . Ultimately, the use of DZNep in studies related to investigating the role of EZH2 inhibition in bioassays should be avoided.
High throughput screening of distinct compound libraries by various groups led to the discovery of non-SAM-derived catalytic inhibitors of EZH2. Remarkably, all the screens identified compounds with a pyridone amide motif, indicating a crucial molecular recognition role for functionality. Although these molecules do not resemble SAM, biochemically they are competitive inhibitors of cofactor binding and various three dimensional homology models have been proposed to rationalize how they may mimic the interactions of the natural substrate. Ultimately, detailed structural studies will be needed to determine unequivocally if both occupy the same binding site in EZH2. Despite these uncertainties, extensive chemical modification of the hits identified in high throughput screening to improve affinity and pharmaceutical properties led to the discovery of analogues [37] [38] [39] (such as those shown in Fig. 2d ), all of which were highly potent, selective and bioavailable inhibitors of EZH2 in biochemical and cellular assays with in vivo antitumour activity in germinal-cell DLBCL with activating EZH2 mutations. Remarkably, these compounds show exquisite selectivity for EZH2 inhibition 
REVIEW INSIGHT
(more than 10,000-fold) over most other methyltransferases and can distinguish from EZH1 inhibition (around 100-fold). One of these compounds (EPZ-6438, also known as E7438) has entered human clinical trials and several others are likely to follow shortly, allowing for an assessment of the therapeutic potential of targeting EZH2 in not only lymphoma but also solid tumours with increased levels of H3K27me3. In this context, the recent report of the activity of an EZH2 inhibitor in a preclinical model of paediatric malignant rhabdoid cancer is notable. A subset of these tumours with inactivated SMARCB1 are thought to be dependent on the catalytic activity of EZH2, and in xenograft models were shown to be sensitive to treatment with the EZH2 inhibitor, EPZ-6438 (ref. 44) . Interestingly, and as mentioned above, other solid tumours (for example, prostate and breast) have also been associated with drastic upregulation of EZH2 expression but surprisingly, no convincing data has emerged showing activity of catalytic EZH2 inhibitors in these cancers. As with many other new potential therapeutics, the safety profile of EZH2 inhibitors remains to be fully defined but initial observations in prolonged animal studies suggest that they are well tolerated with little or no overt toxicity and EPZ-6438 has been advanced to a phase 1/2 clinical trial in patients with advanced solid tumours or with B-cell lymphomas.
Targeting histone demethylases
Previously, methylation was considered to constitute a permanent and irreversible histone modification that defined epigenetic programs in concert with DNA methylation. However, the discovery of lysine-specific demethylase 1 (LSD1, also known as KDM1A, AOF2, BHC110 and KIAA0601) and later the JmjC-domain-containing lysine demethylase family has completely changed this view (for reviews, see refs 45, 46) . LSD1 and its close relative LSD2 (also known as KDM1B and AOF1) belong to the superfamily of flavin adenine dinucleotide (FAD)-dependent monooxidases (Fig. 3a) . The two proteins can catalyse the demethylation of H3K4me2 and H3K4me1, and LSD1 has in addition been shown to catalyse the demethylation of H3K9me2 and H3K9me1 as well as a number of non-histone proteins such as p53, DNMT1 and E2F1.
The JmjC-domain family
In contrast to the LSD demethylases, the JmjC-domain-containing demethylases can also demethylate trimethylated lysines. This catalysis involves an oxidative mechanism requiring iron and 2-oxoglutarate as co-factors and probably occurs through direct hydroxylation of the affected methyl group (Fig. 3b ) 45, 46 . There are 30 of these JmjCdomain-containing proteins in humans, of which 17 have been shown to be active histone lysine demethylases. Several results have associated the histone lysine demethylases with disease, in particular cancer and brain disorders. For instance, members of the JMJD2 (also known as KDM4) family, which can demethylate H3K9me3 and H3K9me2, and H3K36me3 and H3K36me2 have been found to be overexpressed in squamous cell carcinoma, breast cancer and medulloblastoma [47] [48] [49] . Moreover members of the JARID1 (also known as KDM5) family that demethylate H3K4me3 and me2 are overexpressed in breast and bladder cancers 50, 51 , and FBXL10 (also known as KDM2B), specific for H3K36me3 and me2, is overexpressed in leukaemia 52 . Somatic mutations and deletions have also been identified in the JmjC-domain-containing demethylases, including the H3K27me3 and me2 demethylase UTX (also known as KDM6A) that is found mutated in, for instance, multiple myeloma and renal cell carcinoma 27, 28 , and in JARID1C (also known as KDM5C) and PHF8 in patients with X-linked mental retardation 53, 54 . These mutations often lead to loss of a functional demethylase, and because they may be responsible for the disease phenotype, these observations could suggest that the corresponding HMT is a good target for drug development.
Although our understanding of the biological role of the histone demethylases in normal development and disease is still relatively poor, they are considered to be attractive targets for drug development due to their association with disease and their well-defined catalytic mechanism. The use of structure-guided design has recently led to the first highly potent and selective inhibitors to JmjC-domain containing enzymes 55 . These inhibitors, which are competitive with 2-oxoglutarate and non-competitive with a peptide substrate, are potent inhibitors with an half-maximal inhibitory concentration (IC 50 ) in the nanomolar range, and were shown to be specific for the JMJD3 (also known as KDM6B) and UTX H3K27 demethylases. JMJD3 has previously been associated with inflammatory responses, and in agreement with this a JMJD3 and UTX inhibitor reduced proinflammatory cytokine production by human primary macrophages 55 . In addition to showing the relevance of the catalytic activity of JMJD3 in this process, this study provided proof of concept for generating specific JmjC-domain inhibitors. Further proof of concept has been provided by the biotech company EpiTherapeutics, which has developed highly potent inhibitors to the JARID1 family (L.-O. Gerlach, personal communication). These compounds show specific in vivo target engagement of JARID1B, an increase in H3K4me3 levels in treated cells and reduced proliferation of cancer cells in a xenograft mouse model (L.-O. Gerlach, personal communication). These proof-of-concept studies provide support for the idea that JmjC-domain-containing proteins can be targeted by specific compounds, which may have therapeutic applications.
LSD1
It is likely that the first small molecule inhibitors of histone demethylases that enter clinical trials will target LSD1 (ref. 56) (Fig. 3c) . Several data have suggested that LSD1 could be an interesting therapeutic target in cancer because of its high-level expression in prostate cancer, undifferentiated neuroblastoma, oestrogen-negative breast cancer, bladder cancer and colorectal cancer [57] [58] [59] [60] . Nevertheless, the recent demonstration that LSD1 is required for the development and maintenance of acute myeloid leukaemia (AML) has gained the most attention 61, 62 . Specifically, both genetic and pharmacological data have been provided in vitro and in animal models showing that LSD1 is required to sustain the expression of genes induced by the MLL-AF9 oncoprotein and therefore the maintenance of leukaemia stem cells 
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Oryzon Genomics 63 ( Fig. 3c) -that is more specific and 100-fold more potent than TCP 61 . The inhibition of LSD1 in AML led to increased differentiation followed by apoptosis, and consistent with this an increase in expression of differentiation markers (for example, CD11b). The inhibition of LSD1 activity was not associated with a global increase in H3K4me2; however, some increase in H3K4me2 was observed on MLL-AF9 bound genes and genes involved in differentiation 61, 62 . Taken together these studies provide proof of concept for LSD1 as a therapeutic target in leukaemia; however, the mechanism by which LSD1 contributes to leukaemia is not clear for several reasons. First, LSD1 has been found to be part of several chromatin complexes, including the neuronal silencer co-repressor of RE1-silencing transcription factor (CoREST; also known as RCOR1) and the nucleosome remodelling and histone deacetylase NuRD 45 (Fig. 3d) . These complexes are found throughout the genome and have a pleotropic role in transcriptional regulation. Second, LSD1 also binds throughout the genome, especially at active promoters and enhancers 64, 65 . Third, as mentioned above, LSD1 can demethylate H3K9me2 and me1, and H3K4me2 and me1 (Fig. 3d) . H3K9me2 is normally found associated with repressed chromatin and transcriptional silencing, whereas H3K4me2 and me1 are associated with active promoters and enhancers. Inhibition of LSD1 activity in AML did not lead to any change in H3K9me2, whereas an increase of H3K4me2 was observed on MLL-AF9 target genes 61 and CD11b
62
. These observations raise several questions. First, if LSD1 is bound throughout the genome, why does the inhibition of LSD1 lead to the selective increase of H3K4me2 on specific promoters? Second, the expression of MLL-AF9 target genes is decreased in response to LSD1 inhibition, whereas H3K4me2 is increased. This is counterintuitive, because an increase in H3K4me2 is normally associated with increased expression of a gene, as is the case for CD11b. Therefore, what is the mechanism leading to the decreased expression of MLL-AF9 target genes, and how does inhibition of LSD1 lead to differentiation and apoptosis?
Despite the lack of precise mechanistic insight into how LSD1 inhibition can lead to inhibition of leukaemia and prolonged survival of mice, the LSD1 inhibitors seem very promising. Oryzon Genomics has reported on the further development of a clinical compound, ORY-1001, which is more than 1,000 times more potent than TCP and highly selective over related enzymes, including LSD2 (ref. 66) . The structure of ORY-1001 has not been revealed; however, it has been shown to reduce leukaemic stemcell potential, colony formation and to induce differentiation of AML cell lines at subnanomolar concentrations 63 . Moreover, ORY-1001 leads to the time/dose-dependent increase of H3K4me2 at LSD1 target genes (for example, those that encode CD11b) and induction of differentiation markers (T. Maes, personal communication). Oryzon Genomics expects to take ORY-1001 into phase I clinical trials later this year.
Interestingly, the potential use of LSD1 inhibitors is not limited to oncological disease. In fact, the weak LSD1 inhibitor TCP has been used as a non-selective monoamine oxidase inhibitor for the treatment of depression 67 , and because aberrant activity of the REST-CoREST-LSD complex has been implicated in Huntington's disease 68 and LSD1 in herpes infection 69 the LSD1 inhibitors may also be useful for these indications.
Targeting bromodomains
Bromodomains comprise a small family of proteins that recognize and bind to acetylated lysine residues on histone tails (Fig. 4a ). Acting as a scaffold for both the assembly of larger, multi-component macromolecular complexes regulating chromatin accessibility and for the recruitment of key transcriptional proteins such as RNA polymerase, 
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bromodomain-containing proteins are considered 'readers' of the histone code. The human genome encodes more than 50 bromodomain proteins, which can be phylogenetically segregated into eight subfamilies 70 . Embryonic lethality on knockdown of the genes encoding bromodomain containing proteins 71 underscores the primary importance of the proteins in basic cell function, but it has also limited our better understanding of their role in normal and disease physiology. Structurally, bromodomains are made up of a bundle of four alpha helices joined by two closely interacting but sequence variable loops that form an invaginated, largely hydrophobic pocket for binding to the acetylated lysine ligand 70 . The current intense interest in therapeutically targeting various bromodomains originated in the demonstration by GlaxoSmithKline (GSK), the SGC and the Bradner lab that the bromodomain and extraterminal (BET) subfamily (Brd2, Brd3, Brd4 and BrdT) could be targeted by small molecule antagonists 72, 73 . By directly binding to the BET proteins, such compounds prevent the interaction of the reader module to the acetylated histone thereby preventing assembly of an active gene transcriptional complex (Fig. 4a) . The ability to disrupt these proteinprotein interactions with drug-like compounds is remarkable and has been shown in multiple structural studies 67 to be related to the presence of well-defined, deep acetyl lysine binding pockets within the BET proteins. By applying cell-based, high throughput screening of compound libraries combined with elegant chemoproteomics and a battery of structural and biophysical assays, GSK developed compounds that were able to inhibit all four BET proteins but with good selectivity over other bromodomains. Similarly, the SGC working with the Bradner lab developed the widely used JQ1 (Fig. 4b) , originating from a patent application by Mitsubishi-Tanabe 74 . Crucially, the free availability of these compounds to the research community has drastically accelerated our understanding of the primary mechanism of transcriptional regulation and wider chromatin biology. Indeed, the realization that the pharmacological effects of BET inhibition could potentially be applied to ameliorate diverse disease phenotypes has spurred further rounds of compound discovery in pharmaceutical companies.
Early evidence for the potential involvement of BET proteins in cancer was the observation that overexpression of Brd2 in lymphocytes induced B-cell lymphomas. Subsequently, French et al. reported that chromosomal translocation of the Brd4 gene with the NUT protein was the driver for proliferation in the rare but lethal malignancy, NUTmidline carcinoma (NMC) 75 . Furthermore, reversal of the tumour phenotype with BET inhibition not only provided support for the underlying mechanism but also illustrated the therapeutic potential of BET antagonism. Based on this data, a phase I clinical study of the GSK BET inhibitor IBET762 (Fig. 4b) in NMC was initiated in March 2012.
Investigation of the anti-proliferative activity of BET inhibitors in models of haematological cancer, including AML, Burkitt's lymphoma, multiple myeloma and B-cell acute lymphoblastic leukaemia has revealed perhaps the most exciting facet of bromodomain biology 76, 77 . In these malignancies, BET inhibitors such as JQ1 and the more highly bioavailable IBET151 (Fig. 4b ) directly silenced MYC expression through disruption of BET protein binding at the MYC locus. Because the various MYC isoforms are known to be crucial regulators of cell proliferation and survival and MYC is a potent oncogene overexpressed in many cancers, bromodomain antagonism offers, for the first time, an opportunity to target MYC-driven oncogenicity. Intriguingly, however, recent reports have shown crucial subtleties in the mechanism of BET inhibitor modulation of MYC 78 . Whereas in haematological cancers, BET regulates c-MYC, in neuroblastoma, BET inhibitor effects seem to be manifested through silencing of N-MYC, presumably by the same or at least a similar mechanism. These results suggest there is potential for a broader spectrum of activity for BET inhibitors beyond NMC and haematological malignancies, and ongoing clinical studies with IBET762 now include other solid tumours such as N-MYC-amplified lung and colorectal cancers. The question of a therapeutic window for BET inhibitors in a clinical setting remains to be answered but presumably data from animal toxicity studies did not preclude advancing these compounds to human trials.
Outside of cancer, BET inhibition has shown striking effects in a range of inflammatory disease models, suggesting a central role in lymphocyte lineage aetiology. Interestingly, BET inhibition with IBET762 attenuated only secondary response genes in macrophages with no effect on the primary response elements 72 . The ability to modulate selectively the expression of gene subsets is of significance and raises the possibility of further fine-tuning the level of transcriptional activity with selective inhibitors of other bromodomains, which could translate to clinical benefits with fewer undesirable side effects. In mouse models of sepsis, pretreatment with a BET inhibitor suppressed cytokine expression and protected the animals from lethal lipopolysaccharide challenge. In a noteworthy demonstration of activity, administration of the inhibitor even after allergen challenge led to survival 69 . Evidence of the function of other bromodomains (SP110, SP140 and SMARCA4) in immune-mediated diseases driven by loss of memory T cells and B cells is emerging and limited to tantalizing association of bromodomain expression and disease phenotype. It is too early to say whether small molecule inhibitors of other bromodomains or methyl-lysine readers can be successfully identified, but some promising advances have recently been made with BAZ2B and chromodomain proteins associated with brain tumours (Table 1) . The development and availability of additional specific small molecule probes will be needed to help delineate the biology of these proteins.
Perspectives
This is a very exciting and fruitful time for the 'epigenetics field' as illustrated by recent discoveries of new classes of enzymes, insight into the biological role of chromatin-associated proteins, findings showing that somatic mutations in genes coding for chromatin-associated proteins are very frequent in cancer and the development of highly potent and specific small molecule inhibitors to chromatin-associated proteins that show great promise in preclinical trials. Until recently, it was uncertain whether it would be technically feasible to generate specific and potent inhibitors to the different classes of readers, writers and erasers of the histone code. However, as we have discussed in this Review, this has indeed been possible for very diverse enzymatic classes, such as the HMTs, the two different subclasses of histone demethylases and for the non-enzymatic bromodomain-containing proteins. These inhibitors are undergoing or will shortly enter human phase I clinical trials for a variety of oncology indications albeit initially in rare tumour types or haematopoietic malignancies.
A major challenge for a potential expansion of the inhibitors to other tumour types will be to gain a better understanding of the mechanism of action of the drugs, and therefore of the biology of the target protein. The ongoing phase I clinical trials have all been designed based on genetic evidence for a role of the targeted protein in the disease (DOT1L and LSD1 in AML, EZH2 in DLBCL and IBET in NUT-midline carcinoma). Such strong genetic evidence does not currently exist in other tumour types; however, the effect of the specific inhibitors on large, 'omically' well-characterized cell-line panels will hopefully help to identify specific genetic alterations that lead to drug sensitivity. Nonetheless, even this approach is unlikely to be straightforward because most chromatinassociated proteins are present in several different multi-component complexes that are associated with several thousand genes and loci throughout the genome. The biology is therefore complex and, depending on the tissue and the underlying genetic landscape of the cell, the chromatin-associated protein could act as an oncogene in one setting but be a tumour suppressor in other circumstances. This is illustrated, for instance, by EZH2, in which gain-of-function mutations promote lymphoid transformation 16, 33, 37, 79 and loss-of-function mutations promote myelodysplastic syndrome and T-cell acute lymphoblastic leukaemia 36, [80] [81] [82] [83] . Similarly, somatic mutations of lysine 27 of H3.3 found in paediatric glioblastoma have been shown to inhibit EZH2 activity 84 . The dual roles of EZH2 and H3K27 methylation might also reflect the biological role of EZH2 and the PRC2 complex. In contrast to signalling pathways and transcription factors, chromatin-associated proteins and epigenetic regulation do not seem to be decisive for lineage choice during differentiation. Instead these proteins are present in the genome to ensure transcriptional patterns and cell identity. In other words, the chromatin-associated proteins often fine-tune transcriptional patterns, and the genes regulated by the proteins can be both oncogenes and tumour suppressor genes. The functions of the chromatin-associated proteins do not mean that inhibitors of these proteins will not have a clinical benefit, but highlight the difficulty in identifying biomarkers predictive of tumour sensitivity. This is illustrated again by the EZH2 inhibitors, whereby the levels of EZH2 in a tumour cell line do not predict whether the cell line will respond to the inhibitor; however, a weak correlation does exist between the ability of EZH2 inhibitors to decrease H3K27me3 levels in DLBCL and inhibition of cell growth 37 . The generation of small molecule inhibitors of different classes of chromatin-associated proteins has not only increased confidence in the druggability of many epigenetic modulators, but has also provided 
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N strong insights into the rational design of new compounds with higher affinity and specificity. The hope is that this knowledge can be translated into the generation of specific inhibitors of the many other chromatinassociated proteins involved in cancer. At the very least, such inhibitors will be useful as research compounds to understand the biological function of new chromatin-associated proteins, but could eventually also allow for the identification and therapeutic targeting of other pathways that are important for the cancer phenotype. Increasingly, it is becoming evident that effective, long-term responses to anti-cancer therapies require suppression of two or more oncogenic pathways and this is likely to be the case for epigenetic therapies as well. However, modulation of the cancer epigenome with specific inhibitors may offer unique opportunities to discover effective combination therapies based on the potential to directly alter acquired transcriptional resistance mechanisms. Indeed, a recent report 85 demonstrating reversal of platinum resistance with HDAC inhibition in ovarian cancer highlights such opportunities. Undoubtedly, other rational combinations remain to be identified and the challenge will be to understand the fundamental cellular alterations induced by epigenetic modulators and to develop complementary agents that synergize most effectively. Along these lines, the resurgence and current success of immunotherapeutic approaches to cancer treatment also offers opportunities for epigenetically targeted therapeutics. In principle, it may be possible to induce cell surface expression of tumour-specific antigens, allowing for more effective and sustained immune responses to tumours. Finally, the ability to silence crucial oncogenes such as MYC and BCL2 with bromodomain inhibitors has been remarkable and unpredicted. Inactivation of the master oncogenic proteins with small molecules has been the holy grail for anticancer approaches for many years. Yet even here, the lack of a detailed mechanistic understanding of how the BET inhibitors work has led to an empiric approach to determine how best to deploy these agents in the clinic. Despite these limitations, it is important to remember that we are nonetheless on the verge of advancing new molecules with novel biology to human studies with at least some molecular or pathway basis for selecting patients who are most likely to benefit from these agents. Data from these studies will ultimately determine whether these new epigenetic therapies will be a meaningful addition to the armamentarium of physicians, but the signs are promising. ■
